Abstract Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/AKT1 mutations and/or PTEN loss/mutation. Methods The primary endpoint was objective response rate (ORR). https://www.wholelatteslovers.shop/product-category/commercial-grinder/
Commercial Grinder
Internet 7 hours ago oqwpsrx26f5vWeb Directory Categories
Web Directory Search
New Site Listings